In situStimulation of CD40 and Toll-like Receptor 3 Transforms Ovarian Cancer–Infiltrating Dendritic Cells from Immunosuppressive to Immunostimulatory Cells
- 14 September 2009
- journal article
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 69 (18), 7329-7337
- https://doi.org/10.1158/0008-5472.can-09-0835
Abstract
Boosting therapeutically relevant immunity against lethal epithelial tumors may require targeting tumor-induced immunosuppression on an individualized basis. Here, we show that, in the ovarian carcinoma microenvironment, CD11c+MHC-II+ dendritic cells spontaneously engulf tumor materials but, rather than enhancing antitumor immunity, suppress T-cell function. In situ costimulation of CD40 and Toll-like receptor (TLR) 3 on tumor-infiltrating dendritic cells decreased their l-arginase activity, enhanced their production of type I IFN and interleukin-12 (p70), augmented their capacity to process antigens, and up-regulated costimulatory molecules in vivo in mice and in vitro in human dissociated tumors. Synergistic CD40/TLR activation also induced the migration of activated dendritic cells to lymphatic locations and promoted their capacity to present antigens. Correspondingly, without exogenous antigen, combined CD40/TLR agonists boosted measurable T-cell–mediated antitumor immunity and induced the rejection of otherwise lethal i.p. ovarian carcinomas. Our results highlight the potential of transforming tumor-infiltrating dendritic cells (the most abundant leukocyte subset in the solid ovarian carcinoma microenvironment) from an immunosuppressive to an immunostimulatory cell type. Combined administration of synergistic CD40 and TLR3 agonists could enhance their individual therapeutic effects against ovarian and other lethal epithelial cancers. [Cancer Res 2009;69(18):7329–37]Keywords
Other Versions
This publication has 33 references indexed in Scilit:
- Polyethylenimine-based siRNA nanocomplexes reprogram tumor-associated dendritic cells via TLR5 to elicit therapeutic antitumor immunityJCI Insight, 2009
- Tumor-Educated CD11bhighIalow Regulatory Dendritic Cells Suppress T Cell Response through Arginase IPublished by The American Association of Immunologists ,2009
- Tumor-Infiltrating Regulatory Dendritic Cells Inhibit CD8+ T Cell Function via l-Arginine MetabolismCancer Research, 2009
- Depletion of Dendritic Cells Delays Ovarian Cancer Progression by Boosting Antitumor ImmunityCancer Research, 2008
- Enhanced efficacy and reduced toxicity of multifactorial adjuvants compared with unitary adjuvants as cancer vaccinesBlood, 2008
- Cancer Statistics, 2008CA: A Cancer Journal for Clinicians, 2008
- Toll-like receptors and immune regulation: implications for cancer therapyOncogene, 2008
- Control of mesothelin-expressing ovarian cancer using adoptive transfer of mesothelin peptide-specific CD8+ T cellsGene Therapy, 2007
- CD154-CD40 interactions drive hepatocyte apoptosis in murine fulminant hepatitisHepatology, 2005
- Subsets of Human Dendritic Cell Precursors Express Different Toll-like Receptors and Respond to Different Microbial AntigensThe Journal of Experimental Medicine, 2001